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Abstract
Background: Large amounts of low copy number repeats in the 15q11.2q13.3 chromosomal region increase the
possibility of misalignments and unequal crossover during meiosis in this region, leading to deletions, duplications,
triplications and supernumerary chromosomes. Most of the reported cases with epilepsy, autism and Prader-Willi/
Angelman syndrome are in association with rearrangements of the proximal long arm of chromosome 15.
Results: Here we report the first two unrelated Hungarian patients with the same epileptic and dysmorphic features,
who were investigated by array comparative genomic hybridization (array CGH). By G-banded karyotype followed by
FISH and array CGH we could detect partial tetrasomy of the 15q11.2q13.3 chromosomal region, supporting proximal
15q duplication syndrome. Findings of the array CGH gave fully explanation of the phenotypic features of these
patients, including epileptic seizures, delayed development, hyperactivity and craniofacial dysmorphic signs.
Besides the described features of isodicentric (15) (idic(15)) syndrome Patient 1. suffered from bigeminic extrasystoles
and had postnatal growth retardation, which had been published only in a few articles.
Conclusions: Dosage effect of some genes in the concerned genomic region is known, but several genes have no
evidence to have dosage dependence. Our results expanded the previous literature data. We assume dosage
dependence in the case of CHRNA7 and OTUD7A, which might be involved in growth regulation. On the other hand
increased dosage of the KLF13 gene seems to have no direct causal relationship with heart morphology. The genomic
environment of the affected genes may be responsible for the observed phenotype.
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Background
Karyotyping and FISH are essential parts of the clinical
evaluation of patients with epilepsy and dysmorphic fea-
tures. FISH investigation is necessary in cases where
(bi)satellited supernumerary chromosome is present in
order to establish the chromosomal origin and the in-
volvement of Prader-Willi/Angelman region (PWACR)
in those with proven chromosome 15 (chr15) material. In-
creasing usage of array comparative genomic hybridization
(array CGH) in the examination of patients with epilepsy
and dysmorphic features allows the determination of
the correlation between phenotype and genotype. Clin-
ical studies investigated the function of chromosomal
microarray analysis in the diagnosis of patients with epi-
lepsy, and described an association between chromosomal
copy number variations, intrachromosomal rearrange-
ments and epileptic features [1]. Nevertheless, the genetic
background of dysmorphic features remains unidentified
despite the extensive investigation. This complex disease
is associated with several previously described chromo-
somal alterations.
Small supernumerary marker chromosomes derived
from the chr15 (sSMC(15)s) has been more frequently
reported in connection with dysmorphic features and
cause several phenotypes including intellectual disability,
growth deficiency, triangular facies, and brachydactyly
[2,3]. During the formation of this sSMC(15) a transloca-
tion occurs between the homolog chr15s, typically in the
course of maternal meiosis, mediated by the low copy
repeats being present within 15q11-q14. The following
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step is a non-disjunction and usually inactivation of one
of the centromeres. Due to postzygotic correction a mo-
saic state is not uncommon. Within the 15q11q14 region
five common breakpoints were identified (BP1 to BP5).
The classification of sSMC(15)s is based on the eu-
chromatin content (namely on the site of recombin-
ation). In contrast with the small sSMC(15)s containing
the chromosomal material proximal to 15q12 and being
clinically neutral, the larger sSMC(15)s resulting in
partial trisomy or tetrasomy of Prader-Willi/Angelman
region cause abnormal phenotype, in particular when of
maternal origin [4]. Symptoms can vary depending on
location of the breakpoints, copy numbers of the
PWACR region and on the ratio of mosaicism. Clinical
phenotype mostly includes early-onset central hypotonia,
seizures, poor motor coordination, speech delay, moder-
ate to severe learning disability, mild dysmorphic fea-
tures, autism and schizophrenia [5–18]. Cytogenetically
visible duplications (OMIM #608636) of this region are
also reported, and lead to a disorder called 15q duplica-
tion syndrome, mostly manifested by neurobehavioral
phenotypes [19]. These duplications occur mostly in two
forms, including an extra isodicentric 15 (idic (15))
chromosome or an interstitial duplication 15. Based on
previous literature data we can assume that patients with
idic (15) of paternal origin seem to have normal develop-
ment however, maternal aberrations can lead to develop-
mental problems [4,20,21]. In most of the cases the 15q
duplication syndrome is not inherited, but occurs ran-
domly during the formation of reproductive cells. Wide
range of developmental disabilities was experienced in
the case of the individuals with 15q duplication syn-
drome. Examinations of the syndrome could not show
an obvious correlation between the severity of the symp-
toms and the size of the duplicated region. Copy number
changes of this chromosomal region from three to six
have been reported in the literature [4,22,21].
In order to establish the chromosomal content more




We investigated 2 unrelated Hungarian patients with
epilepsy and dysmorphic features.
Patient 1. is a 27 month old boy, first child of a non-
consanguineous healthy young couple (father is 32 and
mother is 31 years old), the mother has a boy from her
first marriage. The family history and the pregnancy
were unremarkable. He was delivered at the 40th week
of gestation with a birth weight of 3200 g (25–50 pc)
and an Apgar score 9/1 and 10/5, respectively. In the
perinatal period cardiological examination was per-
formed because of extrasystole. The Holter monitoring
revealed bigeminic extrasystoles, but it regressed spon-
taneous shortly. His first epileptic seizure developed at
5.5 months of age, and he was never seizure free in spite
of numerous different antiepileptic drug combinations.
His seizure pattern is very variable, and at four years of
age hyperactivity developed. His developmental mile-
stones were delayed, he crept and stood at 18 months,
but he could not walk. Speech development was delayed
as well, only bubbling was present at 28 months.
At 28 months of age as he was first examined in our
institution, his weight was 10 kg (<5 pc), height was
90 cm (50–75 pc) and OFC was 46 cm (<−2 SD). Flat
occipital region, epicanthal folds, hyperteloristic eyes,
crease of earlobes, broad nasal bridge, micrognathia and
severe generalized hypotonia were present.
Patient 2. is a 17 months old girl from the second
pregnancy (G2P1) of a non-consanguineous healthy
young Caucasian couple (both parents are 32 years old),
the family history is unremarkable. The girl was deliv-
ered at 41st weeks of gestation with a birth weight of
3520 g (75–90 pc) and Apgar score 1/10 and 5/10. The
perinatal period was uneventful. Because of developmen-
tal delay she received neurohabilitation from the fourth
month of age and West syndrome developed at the sixth
month. Therefore vigabatrin treatment was administered,
which caused significant seizure frequency reduction.
Congenital brain malformation was supposed in the back-
ground but the performed brain MRI out of dilated frontal
and temporal liquor spaces gave negative results. Her de-
velopmental milestones were delayed. At 12 months she
sat alone and crawled, at 13 months she stood up, but at
17 months her walking capability was yet very unstable.
Her speech development was severely delayed too.
She was referred to our institution because of epilepsy,
dysmorphic features and developmental delay at the age
of 17 months. At the examination her weight was 13 kg
(90 pc), height 85 cm (75–90 pc), OFC 46 cm (−1 SD),
and only mild craniofacial dysmorphic signs (prominent
forehead, flat occiput, broad face, turned-up nose), broad
thorax and small feet could be observed. In her neuro-
logical status severe generalized hypotonia, tiptoe walk-
ing and stereotype hand movements (clapping and
wringing of the hands) were seen.
At her second examination at 29 month of age she
could not walk alone and her walk was yet broad-base.
Babbling started, but she had no clear words. Her
stereotype movements were constant, but her seizure
pattern and the frequency were changed. Therefore val-
proic acid was administered instead of vigabatrin.
Results
GTG banding and FISH
GTG-banded chromosomes at the (550)-band level
showed E-group sized supernumerary acrocentric marker
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chromosome in Patient 1. and an additional bisatellited
chromosome in Patient 2. Because of the clinical symp-
toms/clinical indication metaphase FISH analyses of the
UBE3A locus (Prader-Willi/Angelman Critical Region)
was performed in both cases which showed the presence
of both, the D15Z1 and UBE3A regions (each in two cop-
ies) on the supernumerary marker chromosomes in
addition to the normal chromosomes 15 (four copies in all
in each cells) (Figure 1). Thus, the karyotype of Patient 1.
can be described as 47,XY,+psu idic (15) (pter→
q14::q14→ pter) and that of Patient 2. is 47,XX,+idic
(15)(pter→ q14::q14→ pter). Both abnormalities resulted
in tetrasomy of the 15q11q13 region.
Parental cytogenetic studies were normal.
UPD study
Uniparental disomy of normal chromosomes 15 has
been excluded using polymorphic STR markers. None of
the two patients has uniparental disomy.
Array-based copy number analysis
Array CGH of Patient 1. showed an abnormal male array
profile with copy number gain in the region 15q11.2q13.3
(22,765,628-32,445,252), while in Patient 2. an abnor-
mal female profile with additional dosage of the regions
15q11.2q13.2 (22,765,628-31,183,907) and 15q13.3
(31,261,835-32,861,626), respectively (Figure 2).
Both two investigated patients had gain in copy number
of the 15q11.2q13.3 chromosomal region. Patient 1. had 4
copies of 15q11.2q13.3 (9.68 Mb, chr15:22,765,628-
32,445,252), Patient 2. had 4 copies of 15q11.2q13.2
(8.42 Mb, chr15:22,765,628-31,183,907) and of 15q13.3
(1.6 Mb, chr15:31,261,835-32,861,626) chromosomal
regions, demonstrating that the psu idic(15) contained two
9.68 Mb 15q11.2q13.3 segments (chr15:22,765,628-
32,445,252) in Patient 1. and the + idic(15) contained two
15q11.2q13.2 segments with 8.42 Mb (chr15:22,765,628-
31,183,907) and 1.6 Mb of 15q13.3 (chr15:31,261,835-
32,861,626) regions in Patient 2.
Discussion
Alterations of the 15q11.2q13.3 chromosomal region
lead to a complex phenotypic variability, which greatly
complicates the setting of a specific clinical diagnose.
Here we present the results of the first study of array
CGH analysis in Hungarian patients with epileptic sei-
zures, delayed development, hyperactivity and craniofa-
cial dysmorphic signs where the copy number gain of
the region 15q11.2q13.3 (22,765,628-32,445,252) (Patient
1.), and that of 15q11.2q13.2 (22,765,628-31,183,907)
and 15q13.3 (31,261,835-32,861,626) (Patient 2.) have
been identified in the background of the abnormal
phenotype.
Figure 1 Karyotype and FISH analysis. (a) Karyotype of Patient 1. illustrates the supernumerary chromosome 15. (b) FISH analysis of Patient 1. by
using probes for UBE3A locus (red) at 15q11q13, D15Z1/CEP15 locus (cyan) at 15p11.2 and PML locus (green) at 15q22 illustrates the tetrasomy of
chromosome 15q11q13. (c) Karyotype of Patient 2. illustrates the supernumerary chromosome 15. (d) FISH analysis of Patient 2. by using
probes for UBE3A locus (red) at 15q11q13, D15Z1/CEP15 locus (cyan) at 15p11.2 and PML locus (green) at 15q22 illustrates the tetrasomy of
chromosome 15q11q13
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All of the protein coding genes, occurring in the
15q11.2q13.3 (22,765,628-32,861,626) duplicated region
are shown in the Additional file 1: Table 1 and Figure 3.
Genes within the affected regions are significantly linked to
identified clinical disorders, mainly developmental, heredi-
tary and neurological disorders. (Additional file 2: Table 2).
Based on our findings and previous literature data, we
concluded, that most of the genes within the affected re-
gions are significantly associated with the phenotypic
features of the two analyzed patients. Hypotonia, delayed
motor milestones (sitting up, walking), delayed language
development, progressed hypertonia, and similar facial
characteristics, including flat nasal bridge, epicanthic
and hyperteloristic eyes in Patient 1. can assume a 15q
duplication syndrome that affected the 15q11.2q13.3
(22,765,628-32,445,252) chromosomal region [21]. In
addition to the symptoms were seen in Patient 1., Patient
2. represented typical Angelman like features including
Figure 2 Array-CGH results of the two Hungarian cases. Figure shows the copy number gain of 15q11q13 region in Patient 1 (left) and in Patient
2 (right). Red box illustrates the localization of the copy number gain in Patient1 on chromosome 15. Green box illustrates the positions of the
copy number gains in Patient 2. on chromosome 15
Figure 3 Ensembl results of duplicated regions and the concerned genes. (http://grch37.ensembl.org/Homo_sapiens/Location/Overview?r=15%
3A22765628-32861626) Red line shows the duplicated 15q11q13 region of Patient 1. Green lines show the duplicated regions of Patient 2. The
upper part of the figure illustrates the affected genes. (Red: protein coding; Yellow: merged Ensembl and Havana genes; Purple: RNA genes) The
yellow circles indicate the genes might be involved in growth regulation. The brown circles indicate the genes might be involved in GABA
mediated antiepileptic drug therapy. The blue circle indicates the KLF13 gene, which might be associated to cardiac malformations. The claret
circle indicates the CHRNA7 gene, which might be associated with neuropsychiatric phenotypes
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small feet, turned-up nose, tiptoe walking and stereotype
hand movements (clapping and wringing of the hands).
After uneventful prenatal period, both of our patients
had normal birth weight. By comparing our cases with
the recently published patients investigated by array
CGH and affected by 15q duplication syndrome we
could identify more defined postnatal growth retardation
in the case of Patient 1. (Additional file 3: Table 3). At
28 months of age his weight was only 10 kg (<5 pc),
height was 90 cm (50–75 pc) and OFC was 46 cm (<−2
SD) comparing to Patient 2. with a 13 kg (90 pc) weight
at age 17 months. On the contrary of the previous re-
ported cases our Patient 1. had normal birth weight and
the growth delay occurred subsequently. Proportional
short stature was mentioned previously in many cases,
but postnatal growth delay associated with low weight
was observed to the best of our knowledge only in one
15q13.3 duplicated patient (DECIPHER), in which
CHRNA7 and OTUD7A genes have found within the du-
plicated chromosomal region. The role of the cholinergic
nicotinic receptor CHRNA7 gene has been attributed in
neuropsychiatric disorders, epilepsy, cognitive impair-
ment, furthermore, it is essential for inhibiting cytokine
synthesis by the cholinergic anti-inflammatory pathway
[23]. Dosage sensitivity of the gene has been reported in
patients with 15q13.3 deletion in several cases, among
them in a West-syndrome patient recently [24], and
proved by Valbonesi et al. [25] in a cohort of ADHD pa-
tients where deletion and the resulting lower gene ex-
pression level was investigated. In a three-generation
family with various neuropsychiatric phenotypes, copy
number gain of CHRNA7 showed co-segregation with
the symptoms [26]. Our data/cases provide further evi-
dence for the pathogenicity of copy number gain. Litera-
ture data of the intronless NDN, MAGEL2, MKRN3 and
the NIPA1, NIPA2 genes confirm that these genes are in-
volved in growth regulation, nervous system develop-
ment or transcription. Deletion of the genes in mice and
humans presents failure in nervous system development
and growth regulation [27–29]. Increased dosage of the
mentioned genes could play a role in the development of
postnatal growth retardation.
The group of congenital heart defects is one of the
most common causes of infant morbidity and mortality
with an estimated prevalence of 1-5% of life births.
Congenital heart defects caused by idic (15) duplication
syndrome occur in about 25% of the cases [4] and 7-18%
of patients with the 15q13.3 deletion syndrome (OMIM
612001) had heart defects [30,17,31,32]. Clinical findings
from 15q microdeletion cases pointed that mitral valve
prolapse, slightly enlarged left ventricle, tetralogy of Fallot
and right cardiac hypoplasia with severe tricuspid stenosis
could develop by the deletion of the KLF13 gene of the
BP4BP5 chromosomal region. Kruppel-like transcription
Factor 13 is a well conserved gene, which encodes a mem-
ber of the Kruppel-like family of zinc-finger proteins. The
protein is identified as a regulator of cardiac gene expres-
sion and heart morphogenesis [33,17]. Genetic studies in
the Xenopus embryos also demonstrated a requirement
for KLF13 in cardiac progenitor cell proliferation and
heart morphogenesis [34]. In KLF13 functional knockout
Xenopus embryos normal initial heart development was
observed but, subsequently, the heart was visibly smaller
and showed several defects including a lack of ventricular
trabeculation, atrial septal defects, delayed atrioventricular
cushion formation and maturation of valves [34].
Derwińska et al. presented a 1.6 Mb 15q13.3 duplication
in a patient having cardiac phenotype and suggested that
increased dosage of KLF13 could be the causative of car-
diac anomalies [35]. In our case neither patient showed
cardiac anomalies, although Patient 1. did present bigemi-
nic extrasystole. Based on the limited data available and
on our results, we cannot support Derwińska’s findings
about the association between the increased KLF13 dosage
and cardiac malformations.
Concerning the dosage sensitivity Hamid et. al. reported
in the context of pericentric human chromosomal regions,
that dosage dependent and dosage independent genes
could stand in the background of the clinical effects of the
sSMCs. He stated, that sSMCs containing only dosage in-
dependent genes could be harmless, while dosage
dependent genes in the marker chromosomes could lead
to clinical problems [36].
Regarding to the epilepsy specific treatment of the pa-
tients, antiepileptic drug therapy, using gamma aminobu-
tyric acid transaminase inhibitor vigabatrin and valproic
acid was effective. GABA acts at inhibitory synapses in the
brain by binding to specific transmembrane receptors.
Both of our patients have a gain in the GABA receptor
subunit coding GABRB3, GABRA5 and GABRG3 genes,
which could lead to an increased GABA receptor level.
The used antiepileptic drugs increase the level of the
GABA protein, by inhibiting the GABA metabolism of
GABA transaminases. The higher receptor number associ-
ated with the increased GABA level could be a possible
explanation for the reduced seizure frequency due to the
successful treatment [37–39].
An other database was available [40] containing data of
43 cases with inv dup (15) and seizures. However in this
database 42 cases were investigated only with simple
karyotyping and only one with array CGH. Additional
file 3: Table 3. contains this case. The other 42 patients,
thus could be compared to our cases only based on the
phenotype. Phenotypic manifestation was mostly the same
in our cases and the examined patients, except the pres-
ence of defined postnatal growth retardation in the case of
Patient 1. The lack of array CGH results could not allow
the clarification of the gene-phenotype relationship.
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Conclusions
We identified the first two array CGH examined Hungarian
patients with tetrasomy of the proximal region of chromo-
some 15. Alterations of the 15q11.2q13.3 chromosomal
region cause complex phenotypic variability, which greatly
complicates the setting of a specific clinical diagnose. FISH
analysis followed by array CGH provided clinically rele-
vant information of the investigated patients. The copy
number gain of the 15q11.2q13.3 chromosomal region
could explain the phenotypic presentations characteristic
for idic (15) syndrome observed in the patients, including
epileptic seizures, delayed development, hyperactivity and
craniofacial dysmorphic signs.
In case of a number of genes in the affected chromo-
somal regions dosage effect evidence was reported, how-
ever for certain genes, dosage dependence is not proven.
Based on our findings, we could provide additional in-
formation for previous literature data in case, that in-
creased dosage of CHRNA7 and OTUD7A genes could
lead to postnatal growth delay, so dose dependence of
these genes could be assumed. In contrast, dosage de-
pendence of the KLF13 gene in a patient with an 1.6 Mb
duplication involving the KLF13 gene and in KLF13
knockout Xenopus embryos was presumable, while none
of our patients with higher copy number of KLF13 showed
cardiac anomalies. Thus, our results could not verify the
dosage dependence of the KLF13 gene. However it could
be concluded, that not only the size of the duplicated re-
gion, but the gene content could be responsible for the
whole clinical manifestation. Based on our results we can
assume, that in case of these genes the development of the
expected clinical features could be much better influenced
by the copy number of the genes and their genomic envir-
onment, than only the size of the duplicated genetic ma-
terial itself. Nevertheless, in the case of NDN, MAGEL2,
MKRN3 and the NIPA1, NIPA2 genes confirmation is
needed for the causal relationship between copy number
gain and postnatal growth delay.
Further investigations are necessary to get better know-
ledge regarding to the association between the detailed
genes and the phenotypes they might cause and to the




Karyotyping of the patient was performed by Giemsa–
Trypsin (GTG) banding from peripheral blood lympho-
cytes using standard procedures [41].
Fluorescent in situ hybridization (FISH)
We performed fluorescence in situ hybridization for the
investigation of the supernumerary marker chromosome,
using the 15q11-q13 (D15S10/UBE3A) Prader-Willi/
Angelman probe with 15p11.2 (D15Z1/CEP15) and 15q22
(PML) as control probes (Vysis, Abbott Laboratories,
Abbott Park, Illinois, U.S.A.) [42].
Uniparental disomy study
Uniparental disomy of chromosomes 15 was examined
using previously reported D15S11, D15S97, D15S122,
D15S113, D15S659, D15S128, D15S210, D15S165, D15S10
and GABRB3 polymorphic STR markers [43,44].
Array CGH
Agilent Human Genome Unrestricted G3 ISCA v2 Sure-
print 8x60K oligo-array (Amadid 031746) (Agilent, Santa
Clara, CA) was used for array CGH [45]. This high reso-
lution microarray contains 18,851 60-mer oligo probes
in ISCA regions + 40,208 backbone probes including
coding and non-coding genomic sequences with an aver-
age 60 KB overall median probe spacing, respectively
(higher in ISCA regions).
DNA purification from blood was performed using the
NucleoSpin®Dx Blood DNA Purification Kit (Thermo-
Fisher Scientific, Waltham, MA) applying the protocol
of the producer. We measured the concentration and
purity of the isolated DNA with the NanoDrop spectro-
photometer. For labelling and for hybridization we used
the Agilent Oligonucleotide Array-Based CGH for Gen-
omic DNA Analysis – Enzymatic Labelling Protocol.
1 μg from the patient DNA and from a sex-matched ref-
erence DNA were digested for 2.5 hrs at 37 °C with AluI
and RsaI enzymes. For the labelling of the digested DNA
we applied random priming using the Agilent Genomic
DNA Labelling Kit (Agilent, Santa Clara, CA). Patient
and control DNA were labelled differently. Cy5-dUTP
was used for labelling the patient samples and Cy3-
dUTP for the control samples. Labelled DNA samples
were purified by Amicon Ultra AU-30 filters. The patient
and sex-matched reference samples were combined and
cohybribized at 65 °C for 24 hrs rotation with 50 μg Hu-
man Cot-1 DNA. Washing step was performed using the
Agilent Protocol v7.2. Array image was obtained using
an Agilent laser scanner G2565CA and analysed with
the Agilent FeatureExtraction software (v10.10.1.1.).
The results were presented by Agilent Cytogenomics
software (v2.5.8.11). DNA sequence information refers
to the public UCSC database. The detected chromo-
somal changes were aligned to known aberrations listed
in publicly available databases. We used the DECIPHER
(Database of Chromosomal Imbalance and Phenotype in
Humans using Ensembl Resources), the Database of
Genomic Variants, Ensembl and ECARUCA.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
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images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Additional files
Additional file 1: Table 1. Function of protein coding genes of the
15q11.2q13.3 (22,765,628-32,861,626) chromosomal region according to
Decipher. (https://decipher.sanger.ac.uk/) Notes: Bold: OMIM genes; Italic:
Morbid genes; HI(D): Haploinsufficiency scores from Decipher: values from
0-100%. Low values (0-10%) indicate more likely to exhibit Haploinsufficiency.
The α labeling indicates the genes might be involved in growth regulation.
The β labeling indicates the genes might be involved in GABA mediated
antiepileptic drug therapy. The γ labeling indicates the KLF13 gene, which
might be associated to cardiac malformations. The δ labeling indicates
the CHRNA7 gene, which might be associated with neuropsychiatric
phenotypes.
Additional file 2: Table 2. The list of the genes located in the duplicated
regions and the associated diseases.
Additional file 3: Table 3. Comparing clinical features of array CGH
investigated 15q11q13 duplication patients and our cases. α labeling
indicates the postnatal growth retardation phenotype, while γ labeling
indicates the cardiac symptom of Patient 1.
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